Cargando…

Recent Progress in Rare Oncogenic Drivers and Targeted Therapy For Non-Small Cell Lung Cancer

Non-small cell lung cancer (NSCLC) is frequently associated with oncogenic driver mutations, which play an important role in carcinogenesis and cancer progression. Targeting epidermal growth factor receptor (EGFR) mutations and anaplastic lymphoma kinase rearrangements has become standard therapy fo...

Descripción completa

Detalles Bibliográficos
Autores principales:	Guo, Yijia, Cao, Rui, Zhang, Xiangyan, Huang, Letian, Sun, Li, Zhao, Jianzhu, Ma, Jietao, Han, Chengbo
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Dove 2019
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6886531/ https://www.ncbi.nlm.nih.gov/pubmed/31819518 http://dx.doi.org/10.2147/OTT.S230309

Ejemplares similares

Concurrent Genetic Alterations and Other Biomarkers Predict Treatment Efficacy of EGFR-TKIs in EGFR-Mutant Non-Small Cell Lung Cancer: A Review
por: Guo, Yijia, et al.
Publicado: (2020)

Editorial: Immunotherapy for NSCLC with oncogenic driver variants
por: Du, Yijia, et al.
Publicado: (2022)

Oncogenic driver mutations in lung cancer
por: Luo, Susan Y, et al.
Publicado: (2013)

Immune checkpoint inhibitors and driver oncogenes in non-small cell lung cancer
por: Miura, Yosuke, et al.
Publicado: (2019)

Comprehensive investigation of oncogenic driver mutations in Chinese non-small cell lung cancer patients
por: Wang, Rui, et al.
Publicado: (2015)

Clinical Genotyping of Non–Small Cell Lung Cancers Using Targeted Next-Generation Sequencing: Utility of Identifying Rare and Co-mutations in Oncogenic Driver Genes()
por: Tafe, Laura J., et al.
Publicado: (2016)

Driver oncogenes in Sub-Saharan African patients with non-small cell lung cancer
por: Legius, Barbara, et al.
Publicado: (2016)

Co-Occurring Potentially Actionable Oncogenic Drivers in Non-Small Cell Lung Cancer
por: Zhao, Yiming, et al.
Publicado: (2021)

Oncogenic driver mutations in non-small cell lung cancer: Past, present and future
por: Chevallier, Mathieu, et al.
Publicado: (2021)

The Value of Radiotherapy for Advanced Non-Small Cell Lung Cancer With Oncogene Driver-Mutation
por: Cui, Jinfeng, et al.
Publicado: (2022)

Impact of Drp1-Mediated Mitochondrial Dynamics on T Cell Immune Modulation
por: Song, Jun, et al.
Publicado: (2022)

FAM83H‐AS1 is a noncoding oncogenic driver and therapeutic target of lung adenocarcinoma
por: Wang, Siwei, et al.
Publicado: (2021)

Relationship of driver oncogenes to long term pemetrexed response in non-small cell lung cancer
por: Liang, Ying, et al.
Publicado: (2014)

Targeting MET Amplification as a New Oncogenic Driver
por: Kawakami, Hisato, et al.
Publicado: (2014)

Former smokers with non‐small‐cell lung cancers: a comprehensive investigation of clinicopathologic characteristics, oncogenic drivers, and prognosis
por: Zheng, Shanbo, et al.
Publicado: (2016)

Recent progress in targeted therapy for non-small cell lung cancer
por: Xiao, Yanxia, et al.
Publicado: (2023)

The O-glycosylating enzyme GALNT2 acts as an oncogenic driver in non-small cell lung cancer
por: Hu, Qing, et al.
Publicado: (2022)

Targeted Therapy in Advanced and Metastatic Non-Small Cell Lung Cancer. An Update on Treatment of the Most Important Actionable Oncogenic Driver Alterations
por: König, David, et al.
Publicado: (2021)

Oncogenic drivers and mitochondrial dependency
por: Alvarez-Calderon, Francesca, et al.
Publicado: (2015)

Targeting Oncogenic KRAS in Non-Small-Cell Lung Cancer
por: Sunaga, Noriaki, et al.
Publicado: (2021)

Current Immunotherapeutic Strategies Targeting the PD-1/PD-L1 Axis in Non-Small Cell Lung Cancer with Oncogenic Driver Mutations
por: Tanaka, Ichidai, et al.
Publicado: (2021)

PD-L1 expression and its relationship with oncogenic drivers in non-small cell lung cancer (NSCLC)
por: Jiang, Liyan, et al.
Publicado: (2017)

Comparison of Genomic Driver Oncogenes in Vietnamese Patients With Non–Small-Cell Lung Cancer in the United States and Vietnam
por: Nguyen, Kim-Son H., et al.
Publicado: (2018)

Narrative review: blood and tumor biomarker testing in non-small cell lung cancer without an oncogenic driver
por: Stinchcombe, Thomas E.
Publicado: (2023)

Oncogenic Signalling through Mechanistic Target of Rapamycin (mTOR): A Driver of Metabolic Transformation and Cancer Progression
por: Rad, Ellie, et al.
Publicado: (2018)

GRB7 is an oncogenic driver and potential therapeutic target in oesophageal adenocarcinoma
por: Gotovac, Jovana R, et al.
Publicado: (2020)

SMYD3: An Oncogenic Driver Targeting Epigenetic Regulation and Signaling Pathways
por: Bottino, Cinzia, et al.
Publicado: (2020)

STAT3 Is Activated by JAK2 Independent of Key Oncogenic Driver Mutations in Non-Small Cell Lung Carcinoma
por: Looyenga, Brendan D., et al.
Publicado: (2012)

ALK Deletion Exons 2 to 19: Case Report of a Rare ALK Inhibitor–Responsive Lung Cancer Driver Oncogene
por: Schoepflin, Zachary R., et al.
Publicado: (2023)

Metastatic Progression of Osteosarcomas: A Review of Current Knowledge of Environmental versus Oncogenic Drivers
por: Odri, Guillaume Anthony, et al.
Publicado: (2022)

Beyond epidermal growth factor receptor: MET amplification as a general resistance driver to targeted therapy in oncogene-driven non-small-cell lung cancer
por: Coleman, N., et al.
Publicado: (2021)

Small molecule inhibitors reveal PTK6 kinase is not an oncogenic driver in breast cancers
por: Qiu, Luping, et al.
Publicado: (2018)

Anti-PD1/PD-L1 Immunotherapy for Non-Small Cell Lung Cancer with Actionable Oncogenic Driver Mutations
por: Dantoing, Edouard, et al.
Publicado: (2021)

The EML4-ALK oncogene: targeting an essential growth driver in human cancer
por: MANO, Hiroyuki
Publicado: (2015)

Immuno-targeted combinations in oncogene-addicted non-small cell lung cancer
por: Listì, Angela, et al.
Publicado: (2019)

The long tail of oncogenic drivers in prostate cancer
por: Armenia, Joshua, et al.
Publicado: (2018)

Oncogenic Viruses as Entropic Drivers of Cancer Evolution
por: Tempera, Italo, et al.
Publicado: (2021)

Spectrum of Oncogenic Driver Mutations in Lung Adenocarcinomas from East Asian Never Smokers
por: Li, Chenguang, et al.
Publicado: (2011)

Real-World Evidence of Diagnostic Testing for Driver Oncogene Mutations in Lung Cancer in Japan
por: Yatabe, Yasushi, et al.
Publicado: (2020)

FANCA deficiency promotes leukaemic progression by allowing the emergence of cells carrying oncogenic driver mutations
por: Pawlikowska, Patrycja, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_1iad0b1lbqb8l18rtqjbjspqm3